Home » Market News » DirectorsTalk Highlights » Hesitating to test staff “may prevent valuable, safe treatments from seeing the light of day”
Open Orphan PLC

Hesitating to test staff “may prevent valuable, safe treatments from seeing the light of day”

Employers hoping to get more staff back to work by using coronavirus antibody tests have been warned that they could miss one in 10 cases of Covid-19.

According to researchers at the University of Birmingham, the tests are not accurate enough to confirm whether someone has had the virus if used in the first two weeks after symptoms appear.

But Cathal Friel, chief executive of antibody testing kit manufacturer hVIVO, said hesitating to test staff “may prevent valuable, safe treatments from seeing the light of day and making the UK workforce productive once again”.

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data). 

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.